A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).

Christos Papadimitriou(National and Kapodistrian University of Athens), Wolfgang Janni(Grace (United States)), Michelle DeSilvio(Newark Beth Israel Medical Center), Piotr Potemski(Copernicus Memorial Hospital), Tomasz Sarosiek, Joanna Pikiel(Chemotherapy Foundation), Bogusława Karaszewska(State University of Applied Sciences in Konin), Kathryn Jane Briggs(GlaxoSmithKline (United Kingdom)), Luca Marini, Étienne Brain(Institut Curie), Christoph Salat(Praxis für Hämatologie und Onkologie), Christian Caglevic
Journal of Clinical Oncology
May 20, 2013
10.1200/jco.2013.31.15_suppl.516
Cited by 6

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k